Liquidia Technologies Inc saw a notable increase in its stock price, fueled by strong sales of its innovative treatment.
Liquidia Technologies Inc (NASDAQ:LQDA) experienced a surge in its stock price, climbing 5.13% in yesterday's trading session. This uptick comes on the heels of impressive sales figures for its recently launched drug, Yutrepia, which has quickly become a key growth driver for the company.
Advertisement
Liquidia Technologies Inc
LQDA.US
LQDA.US
Liquidia Technologies Inc
WealthAwesomeMarket cap
$6.35B
P/E
48.3x
52W high
$93.61
52W low
$21.35
1W change
+3.74%
Beta
0.54
Analyst Price Targets
Based on 10 analysts covering LQDA · as of Sep 17, 2026
Wall Street analysts forecast LQDA stock price to rise 51.9% over the next 12 months.
Consensus
Buy4.30 / 5.00
Avg. Target
C$107.75
+51.9% Upside
Current Price
C$70.95
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LQDA's historical volatility
30-Day Vol
50.6%
Annualized
90-Day Vol
58.9%
Annualized
Trend (90d)
-49.0%
Annualized drift
90d Mean
C$59.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$66.93 | C$56.21 – C$79.69 |
| 60 trading days | C$63.14 | C$49.33 – C$80.81 |
| 90 trading days | C$59.56 | C$44.02 – C$80.58 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The strong sales performance of Yutrepia indicates robust market demand, but investors should remain cautious about the competitive landscape in the pulmonary arterial hypertension market.
Yutrepia generated approximately $300.3 million in sales in the first half of 2026.
The drug has recorded about 5,900 unique prescriptions since its launch, indicating strong initial market acceptance.
Bull case
Yutrepia's unique formulation and quick adoption by healthcare providers put Liquidia in a good position for continued growth, especially if the company can successfully expand into new treatment areas.
Bear case
Growing competition from established players like United Therapeutics and new therapies from companies like Insmed could make it harder for Liquidia to keep its growth momentum in the PAH market.
Strong Sales Performance
Advertisement
Liquidia's Yutrepia has generated approximately $300.3 million in sales during the first half of 2026, showcasing its rapid adoption in the market. The inhaled dry-powder formulation of treprostinil, developed using Liquidia's proprietary PRINT technology, allows for deeper delivery into the lungs, making it a compelling option for patients with pulmonary arterial hypertension (PAH).
Competitive Landscape
Despite the positive sales figures, Liquidia faces significant challenges from established competitors like United Therapeutics, which has a long-standing presence in the PAH market with its inhaled therapies. Additionally, emerging therapies from companies like Insmed could further complicate Liquidia's efforts to capture market share, making it crucial for the company to differentiate Yutrepia and expand its indications.
Looking Ahead
As Liquidia continues to navigate the competitive landscape, its ability to sustain growth will depend on strategic decisions regarding market positioning and the development of new indications for Yutrepia. Investors should monitor these developments closely, as they will play a key role in the company's future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
